<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEPERIDINE HYDROCHLORIDE</span><br/>(me-per'i-deen)<br/><span class="topboxtradename">Demerol, </span><span class="topboxtradename">Pethadol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Pethidine Hydrochloride <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist analgesic</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>B (D at term)<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg tablets; 50 mg/5 mL syrup; 10 mg/mL, 25 mg/mL, 50 mg/mL, 75 mg/mL, 100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic morphine-like compound. Chemically dissimilar to morphine, but in equianalgesic doses it is qualitatively comparable.
         Usual doses produce either no pupillary change or slight miosis, but overdosage results in marked miosis or mydriasis. Also,
         unlike morphine, has little or no antidiarrheic or antitussive action. Produces CNS stimulation in toxic doses.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Control of moderate to severe pain.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of moderate to severe pain, for preoperative medication, for support of anesthesia, and for obstetric analgesia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to meperidine; convulsive disorders; acute abdominal conditions prior to diagnosis; pregnancy prior to labor
         [(category B), at term (category D)], lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Head injuries, increased intracranial pressure; asthma and other respiratory conditions; supraventricular tachycardias; prostatic
         hypertrophy; urethral stricture; glaucoma; older adult or debilitated patients; impaired kidney or liver function, hypothyroidism,
         Addison's disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/SC/IM/IV</span> 50150 mg q34h prn<br/><span class="rdage">Child:</span> <span class="rdroute">PO/SC/IM/IV</span> 11.5 mg/kg q34h (max: <img src="../images/special/lesserorequal.gif"/>100 mg q4h) prn<br/><br/><span class="indicationtitle">Preoperative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 50150 mg 3090 min before surgery<br/><span class="rdage">Child:</span> <span class="rdroute">IM/SC</span> 12.2 mg/kg 3090 min before surgery<br/><br/><span class="indicationtitle">Obstetric Analgesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 50100 mg when pains become regular, may be repeated q13h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give syrup formulation in half a glass of water. Undiluted syrup may cause topical anesthesia of mucous membranes.</li>
</ul><span class="adminroutetype">Subcutaneous and Intramuscular Injections</span><br/><ul>
<li>Be aware that SC route is painful and can cause local irritation. IM route is generally preferred when repeated doses are
            required.
         </li>
<li>Aspirate carefully before giving IM injection to avoid inadvertent IV administration. IV injection of undiluted drug can cause
            a marked increase in heart rate and syncope.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion/injection for administration to infants or children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 50 mg in at least 5 mL of NS or sterile water to yield 10 mg/mL.  <span class="methodtype">IV Infusion:</span> Dilute to a concentration of 110 mg/mL in NS, D5W, or other compatible solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate not to exceed 25 mg/min. Slower injection preferred.  <span class="methodtype">IV Infusion:</span> Usually given through a controlled infusion device at a rate not to exceed 25 mg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<span class="classification">barbiturates</span>, <b>floxacillin,</b>
<b>furosemide,</b>
<b>heparin,</b>
<b>methicillin,</b>
<b>morphine,</b>
<b>phenytoin,</b>
<b>sodium bi-carbonate.</b>
<span class="incompattype"> Y-site:</span>
<b> Allopurinol,</b>
<b>amphotericin B cholesteryl complex, cefepime,</b>
<b>cefoperazone,</b>
<b>doxorubicin liposome,</b>
<b>furosemide,</b>
<b>heparin,</b>
<b>idarubicin,</b>
<b>imipenemcilastatin,</b>
<b>mezlocillin,</b>
<b>minocycline,</b>
<b>tetracycline.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in tightly closed, light-resistant containers unless otherwise
            directed by manufacturer.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergic (<span class="speceff-common">Pruritus,</span> urticaria, skin rashes, wheal and flare over IV site), profuse perspiration. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness,</span> weakness, euphoria, dysphoria, <span class="speceff-common">sedation,</span> headache, uncoordinated muscle movements, disorientation, decreased cough reflex, miosis, corneal anesthesia, <span class="speceff-life">respiratory depression</span>. Toxic doses: muscle twitching, tremors, hyperactive reflexes, excitement, hypersensitivity to external stimuli, agitation,
      confusion, hallucinations, dilated pupils, <span class="speceff-life">convulsions</span>. <span class="typehead">CV:</span> Facial flushing, light-headedness, hypotension, syncope, palpitation, bradycardia, tachycardia, <span class="speceff-life">cardiovascular collapse, cardiac arrest (toxic doses)</span>. <span class="typehead">GI:</span> Dry mouth, <span class="speceff-common">nausea,</span> vomiting, <span class="speceff-common">constipation,</span> biliary tract spasm. <span class="typehead">Urogenital:</span> Oliguria, urinary retention. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory depression in newborn, bronchoconstriction</span> (large doses). <span class="typehead">Skin:</span> Phlebitis (following IV use), pain, tissue irritation and induration, particularly following subcutaneous injection. <span class="typehead">Metabolic:</span> Increased levels of serum amylase, BSP retention, bilirubin, AST, ALT. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>High doses of meperidine may interfere with <span class="alt">gastric emptying studies</span> by causing delay in gastric emptying.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span>, <b>cimetidine</b> cause additive sedation and CNS depression; <span class="classification">amphetamines</span> may potentiate <span class="classification">CNS</span> stimulation; <span class="classification">mao inhibitors</span>, <b>selegiline,</b>
<b>furazolidone</b> may cause excessive and prolonged CNS depression, convulsions, cardiovascular collapse; <b>phenytoin</b> may increase toxic meperidine metabolites. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may increase sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 5060% absorbed from GI tract. <span class="typehead">Onset:</span> 15 min PO; 10 min IM, SC; 5 min IV. <span class="typehead">Peak:</span> 1 h PO, IM, SC. <span class="typehead">Duration:</span> 24 h PO, IM, SC; 2 h IV. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> excreted in urine. <span class="typehead">Half-Life:</span> 35 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Give narcotic analgesics in the smallest effective dose and for the least period of time compatible with patient's needs.</li>
<li>Assess patient's need for prn medication. Record time of onset, duration, and quality of pain.</li>
<li>Note respiratory rate, depth, and rhythm and size of pupils in patients receiving repeated doses. If respirations are 12/min
            or below and pupils are constricted or dilated (see <small>ACTIONS AND USES</small>) or breathing is shallow, or if signs of CNS hyperactivity are present, consult physician before administering drug.
         </li>
<li>Monitor vital signs closely. Heart rate may increase markedly, and hypotension may occur. Meperidine may cause severe hypotension
            in postoperative patients and those with depleted blood volume.
         </li>
<li>Schedule deep breathing, coughing (unless contraindicated), and changes in position at intervals to help to overcome respiratory
            depressant effects.
         </li>
<li>Chart patient's response to drug and evaluate continued need.</li>
<li>Repeated use can lead to tolerance as well as psychic and physical dependence of the morphine type.</li>
<li>Be aware that abrupt discontinuation following repeated use results in morphine-like withdrawal symptoms. Symptoms develop
            more rapidly (within 3 h, peaking in 812 h) and are of shorter duration than with morphine. Nausea, vomiting, diarrhea,
            and pupillary dilatation are less prominent, but muscle twitching, restlessness, and nervousness are greater than produced
            by morphine.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not smoke and walk without assistance after receiving the drug. Bed side rails may be advisable.</li>
<li>Be aware nausea, vomiting, dizziness, and faintness associated with fall in BP are more pronounced when walking than when
            lying down (these symptoms may also occur in patients without pain who are given meperidine). Symptoms are aggravated by the
            head-up position.
         </li>
<li>Do not drive or engage in potentially hazardous activities until any drowsiness and dizziness have passed.</li>
<li>Do not take other CNS depressants or drink alcohol because of their additive effects.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>